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AIMS: To compare different methods in order to assess adherence and persistence with oral endocrine therapy in women diagnosed
with breast cancer (BC) in Catalonia.
MATERIALS AND METHODS: This study covered all women newly diagnosed with stage I, II or IIIa BC and positive hormone receptors at
six hospitals in Catalonia (Spain) in 2004. Adherence was assessed on the basis of physician report and patient self-report using a
telephone questionnaire. Persistence was measured by refill prescriptions. We used the Kappa index to compare adherence
measures and logistic regression to evaluate adherence-related risk factors.
RESULTS: The study covered a total of 692 women. Adherence ranged from 92% (self-report) to 94.7% (physician report), depending
on the measure used; persistence was 74.7% at 5 years of follow-up. Low concordance between measures was observed (Kappa
range: 0.018–0.267). Patients aged 50–74 years showed higher adherence than those aged o50 years. Adherence was also
associated with: adjuvant chemotherapy and sequential hormonal therapy.
CONCLUSIONS: Concordance between the different measures was remarkably low, indicating the need for further research. Adherence
is an issue in the management of BC patients taking oral drugs, and should be assessed in clinical practice.
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Breast cancer (BC) is the most frequent cancer among women,
accounting for 28.1% of all cancer diagnosed in Catalonia in the
period 1998–2002 (Borras et al, 2009). Early detection, screening
and improvements in therapy have increased the life expectancy
and quality of life these patients (Berry et al, 2005). One such
improvement is adjuvant treatment of BC patients, which,
depending on the disease stage and other prognostic factors,
could take the form of one or more of the following procedures:
radiotherapy; chemotherapy; target therapy; and oral endocrine
treatment. Clinical guidelines recommend that hormone receptor-
positive BC patients receive at least 5 years of oral endocrine
therapy (Manchon et al, 2010). Tamoxifen reduces risk of
progression and death (Early Breast Cancer Trialist’
Collaborative Group (EBCTCG), 2005; Lash et al, 2006). Aromatase
inhibitors have demonstrated superiority to tamoxifen, whether
alone or in sequence with tamoxifen in postmenopausal women
with BC (Mouridsen et al, 2009).
One of the most relevant issues linked to chronic diseases is lack
of adherence to therapy. Low adherence to treatment may
influence its efficacy and increase health service use and associated
costs (Haynes et al, 1977; Darkow et al, 2007). DiMatteo (2004)
conducted a review of the studies published in the last 50 years
and observed that average adherence for all types of disease and
treatment was 76.2% overall. Although there are a number
of different methods for assessing adherence to treatment, there
is no consensus as to which could be considered a gold
standard (Rudd, 1979). Direct methods are all objective but
are costly and difficult to apply in clinical practice; and, while
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indirect methods, such as patient interviews, are less expensive and
easy to implement, they can nonetheless be biased, usually towards
overestimating adherence (Wang et al, 2004). Recently, the
monitoring of prescribed, refilled and reimbursed medical
treatment from community or hospital pharmacies has been used
(Andersson et al, 2005), a methodology that has been applied in
studies targeting BC patients (Nilsson et al, 2006). Behaviour
related to drug taking has been divided into two distinct –
although closely related – concepts, namely, adherence and
persistence. Whereas adherence refers to the frequency of drug
use during therapy (how well a patient is taking the prescribed
drug), persistence refers to the overall duration of therapy (how
long a patient has been taking the drug) (Cramer et al, 2008).
Until recently, the problem of non-adherence was not a subject of
major interest in cancer care, due mainly to the fact that almost all
therapies were parentally administered in a hospital setting (though
it should perhaps be mentioned here that non-adherence is also a
problem in parenteral cancer drugs) (Borras et al, 2001). However,
the recent development of oral therapies in oncology could mark a
turning point in the perceived need for assessing adherence among
cancer patients. Moreover, patients tend to prefer oral therapies to
parenteral drugs (Liu et al, 1997; Fallowfield et al, 2006).
There were no data for southern Europe that would have
enabled the extent of the problem posed by non-adherence to be
assessed, by using a range of measures to analyse concordance
among them. We carried out a 5-year follow-up study of patients
first diagnosed with early BC in Catalonia in 2004. The main aim of
this study was to assess the degree of adherence to endocrine
adjuvant therapy, and the consistency between different measures
of adherence, which were deemed feasible in daily clinical practice.
MATERIALS AND METHODS
Study population
A retrospective study was designed, including all new patients
diagnosed with BC during 2004 at six hospitals in the city of
Barcelona and the Greater Barcelona area (Catalonian Institute
of Oncology-Duran i Reynals Hospital, Catalonian Institute of
Oncology-Gemans Trias i Pujol, Santa Creu i Sant Pau Hospital,
del Mar Hospital, Terrassa Health Consortium, Parc Taulı´ Health
Corporation). Breast cancer patients were identified by means of
hospital registries and the minimum basic data set for all patient
discharges, which is mandatory in the Catalonian Health Service.
All patients diagnosed at the participating health centres in 2004
were reviewed (N¼ 1133) and found that 61% of patients met the
inclusion criteria, that is, case of histologically confirmed, incident,
invasive BC in stages I, II or IIIa, with analysis of hormonal-positive
receptors and at least one prescription for adjuvant endocrine
treatment (Manchon et al, 2010). Information was collected between
November 2009 and April 2010. The study protocol was reviewed
and approved by the ethics committees of all the participating
hospitals. Informed consent was obtained from all patients.
Data sources and measures used
Clinical records were reviewed to collect data on tumour
characteristics, stage and hormone receptors (oestrogens and
progesterone), along with any indication of adjuvant endocrine
treatment, adherence as recorded in the clinical record, side effects
recorded in patients’ clinical records and patients’ vital status.
A telephone interview was conducted by trained personnel, using a
standard structured questionnaire to gather information on
adjuvant oral endocrine therapy, adherence and problems
experienced in taking the medication as reported by the patient.
Finally, data on the use of endocrine therapy for BC treatment over
the study period (2004–2009) was drawn from the community
pharmacy database of refill prescriptions, which is mandatory for
reimbursement of the therapies in Spain.
For study purposes, treatment persistence and adherence were
deemed to be outcomes. As proposed by Cramer et al (2008),
adherence was defined as ‘the extend to which a patient acts in
accordance with the prescribed interval and dose of a dosing
regimen’ and persistence as ‘the duration of time from initiation to
discontinuation of therapy’. Discontinuation of therapy was
considered when prescription was not refilled for more than 2
months. A change of drug was considered as a continuation of
treatment. The study follow-up time was 5 years from the date of
the first prescription refill. Where recurrence or death occurred,
this was taken as the last date for persistence analysis.
Three different data sources were used, namely:
Physician report Adherence was measured as reported by
patients’ physicians in their clinical records.
Telephone questionnaire To measure adherence, all patients were
telephonically interviewed using the following question, ‘How
often do you have difficulties in taking your medicine or do you
ever forget to take it?’, to which possible answers were, ‘never’,
‘sometimes’, ‘quite a lot’, ‘all the time’ and ‘I do not remember’.
One variable was defined to assess level high of adherence with
women who answered ‘never’ or ‘sometimes’.
Administrative drug-reimbursement database This is a manda-
tory register of all refilled prescriptions at pharmacies requiring
reimbursement by the Catalonian Health Service. All patients
included had received treatment at a public hospital, and as a
result the database furnished full coverage on such cases.
Treatment persistence was estimated as the proportion of days
covered during the prescribed treatment period. Data were
computed up to a maximum of 5 years from the date of the first
prescription refill, thus it could be considered a cumulative 5 years
measure of adherence. Both persistence and adherence was
deemed satisfactory if coverage of the prescribed medication was
80–110% (Hershman et al, 2010b).
Statistical analysis
The outcome obtained from the three different data sources were
assessed individually. Persistence was transformed in categorical
variable in accordance to the 80–110% coverage of the prescribed
medication to be comparable with the other outcomes. Adherence
is used the outcome variable with the three different sources of
information collected in this study univariate comparison between
categorical and dependent variables was performed using a w2-test.
Unconditional logistic regression was applied to estimate the odds
ratios (OR) and 95 per cent confidence intervals (CI, 95% CI) of
non-adherence to oral hormone therapy vis-a`-vis different factors,
with adherent or persistent patients taken as the reference group.
Models were adjusted for age (o50, 50–74 and474 years old were
the categories applied), hospital and those variables associated in
the univariate analysis (Po0.1) for each dependent measure of
adherence. Concordance among the three methods used to assess
adherence was estimated by means of the Kappa index (Landis and
Koch, 1977). The level of significance was set at 5% and all tests
were two-tailed. Adverse effects were analysed as a dichotomous
variable reporting the presence or absence of them for individual
patients. All analyses were performed using the SPSS (version 13.0,
September 2004) software programme.
RESULTS
A total of 692 women fulfilled the inclusion criteria (Figure 1).
Descriptive demographic and clinical data on all patients in the
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study sample are shown in Table 1. The main surgical treatment
was conservative breast surgery (79%). In all, 89% thus received
chemotherapy and/or radiotherapy. The most frequent endocrine
therapies were tamoxifen and anastrozole as one-drug treatment,
and tamoxifen followed by exemestane as sequential therapy.
Disease progression was observed in 8% of cases.
Although the lowest adherence was observed for the Adminis-
trative drug-reimbursement database (74.7% adjusted for age,
centre and stage), the highest adherence was observed for
physician report (94.7%) (Table 2). Concordance among the three
methods was very low (range:  0.018 to 0.267), showing an
almost non existent consistency in the reports of adherence by the
three measures used.
Table 3 showed the multivariate analysis of the different
measures of treatment adherence and their association with the
potential explanatory variables. Insofar as physician-assessed
adherence was concerned, age was associated with adherence,
with women aged 50–74 years and over being more likely to be
adherents (OR¼ 1.71, 95% CI: 0.72–4.06 and OR¼ 2.56, 95% CI:
0.68–9.63, respectively) than those aged under 50 years. Further-
more, adjuvant chemotherapy (OR¼ 2.14, 95% CI: 1.01–4.53)
increased the probabilities of adherence to treatment. Patients who
received sequential endocrine treatment showed a higher adher-
ence than those who received one-drug treatment. Women treated
with radiotherapy showed a higher probability of adherence
(OR¼ 1.8, 95% CI: 0.8–4.05). Women with reported side effects on
physician report were two-fold more likely to be adherent than
those who did not (OR¼ 1.81, 95% CI: 0.81–4.02); when adherence
was self-reported by patients high, an association was observed
with age, with women aged 50–74 years proving significantly more
adherent than those aged under 50 years (OR¼ 2.75, 95% CI: 1.41–5.36).
The presence of adverse drug effects was not associated with
adherence.
Age, endocrine treatment and adjuvant chemotherapy were
associated with adherence to treatment measured by the
prescription refill of the drug. Women aged 50–74 years and
those aged over 74 years showed a higher probability of adherence
(OR¼ 1.67, 95% CI: 1.03–2.70 and OR¼ 1.60, 95% CI: 0.76–3.36,
respectively). Similarly, higher probability of adherence with
endocrine treatment (OR¼ 1.60, 95% CI: 1.05–2.43) was observed
for women receiving adjuvant chemotherapy treatment. Patients
with aromatase inhibitors only and sequential therapy (tamoxifen
þ aromatase inhibitors) showed a higher probability of being
adherent as compared with those with Tamoxifen only (OR¼ 2.0,
95% CI: 1.18–3.38 and OR¼ 2.27, 95% CI: 1.34–3.84, respectively).
Finally, we observed a non significant increase in probability
of adherence in the presence of side effects (OR¼ 1.25, 95% CI:
0.81–1.93).
DISCUSSION
The results of this study suggest that adherence by BC patients to
endocrine treatment over the course of 5 years is a problem that
calls for ongoing assessment by physicians in clinical practice.
However, while adherence measured by refill prescriptions during
the cumulative 5 years of treatment showed 74.7% adherence,
physicians reported much higher adherence (94.7%) and patient’s
92.% of adherence. Hence, the variable used to measure adherence
is critical when it comes to identifying adherence problems among
BC patients.
The range of values observed in our study are consistent with
those to be found in the literature (Partridge et al, 2003, 2008;
Barron et al, 2007; Ruddy et al, 2009; Verma et al, 2011; Banning,
2012). A recent review of different oral cancer treatments reported
persistence of 50–79% based on refill records (Ruddy et al, 2009).
Using similar approaches, other recently published studies
indicate lower percentages than those observed by us, that is,
cumulative 5-year persistence levels of 49% in a Dutch cohort
(Herk-Sukel et al, 2010) and 68% in another US population
(Hershman et al, 2010a). Self-report measures yielded more
inconsistent results: while one study used a single measure to
report an adherence figure of 45% (Atkins and Fallowfield, 2006),
another that relied on the self-reported answers of the sample
reported adherence of 100%, which then fell to 80% for tamoxifen
and 60% for anastrozole (Ziller et al, 2009) when drug refills were
used as the measure. It is of interest to note that, of all the
measures used, it was physicians’ reports that indicated the highest
adherence levels, which probably implies an overestimation of
patients’ adherence to treatment (Rudd, 1979; Partridge, 2006).
Taking all the observed measures into consideration, our study
shows that 5.3–25.3% of patients failed to follow the prescribed
course of oral endocrine treatment. Such non-adherence has
clinical consequences in terms of disease prognosis, as was
recently shown by a Scottish study which observed a 10% higher
risk of death (hazard ratio¼ 1.10, 95% CI: 1.001–1.21) associated
with adherence to tamoxifen of under 80%, (McCowan et al, 2008)
though cumulative 5-year persistence was lower in their case (49%)
than in ours. Similarly, over  80% adherence was seen by another
paper to be associated with a lower risk of death. Indeed, this 80%
cutoff is clearly supported (Hershman et al, 2010b), to the extent
that any decrease in adherence below this point is accompanied by
an increase in the risk of death.
However, as mentioned above, one crucial aspect that emerges
from the literature is the problem of measuring adherence (Ruddy
et al, 2009), and this study allows to consider in a comparative
approach. As a background, here is no gold standard for adherence
measurement, this fact has as a consequence that there is a
diversity of measures used. The fact that our study design made
use of different approaches to measure adherence assessed by
physician, by the patient and the cumulative 5 years persistence
with the refill of the treatment afforded us an opportunity to assess
the consistency of the different variables used. Our results clearly
Breast cancer in 2004
n = 1133
Study population
n = 692 (61.1%)
Clinical
report
n = 692
Telephone
interview
n = 506
Administrative
database
n = 673
441 failed to fulfil inclusion criteria
Histological confirmation  before 2004
Negative hormonal receptors
Stage <> I, II or IIIa
Others
Death
Recurrence
Clinical trials
Lost to follow-up
38.6%
29.9%
38.6%
9.1%
7.6%
7.7%
12.9%
4.5%
Figure 1 Flow chart of participants.
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Table 1 Description of the clinical variables of patients
Tamoxifen Inhibitors Tamoxifen þ inhibitors Others
n (%)a n (%)b n (%)c n (%)d
Endocrine therapy 200 206 243 43
Age at diagnosis
p49 years 110 (55.0) 10 (4.9) 47 (19.3) 16 (37.2)
50–74 years 69 (34.5) 143 (69.4) 185 (76.1) 22 (51.2)
X75 years 21 (10.5) 53 (25.7) 11 (4.5) 5 (11.6)
Stage
I 101 (50.5) 83 (40.3) 120 (49.4) 17 (39.5)
IIA 55 (27.5) 63 (30.6) 69 (28.4) 13 (30.2)
IIB 29 (14.5) 29 (14.1) 30 (12.3) 5 (11.6)
IIIA 8 (4.0) 15 (7.3) 15 (6.2) 4 (9.3)
TNMx 7 (3.5) 16 (7.8) 9 (3.7) 4 (9.3)
Surgical treatment
Yes 194 (97.0) 201 (97.6) 243 (100.0) 43 (100.0)
No 6 (3.0) 5 (2.4) 0 0
Type of surgical treatment
Conservative breast surgery 149 (76.8) 148 (73.7) 208 (85.6) 31 (72.1)
Radical breast surgery 45 (23.2) 53 (26.4) 35 (14.4) 12 (27.9)
Radiotherapy
Yes 155 (77.5) 157 (76.2) 216 (88.9) 32 (74.4)
No 45 (22.5) 49 (23.8) 27 (11.1) 11 (25.6)
Neoadjuvant chemotherapy
Yes 26 (13.0) 10 (4.9) 51 (21.0) 7 (16.3)
No 174 (87.0) 196 (95.1) 192 (79.0) 36 (83.7)
Adjuvant chemotherapy
Yes 100 (50.0) 73 (35.4) 167 (68.7) 21 (48.8)
No 100 (50.0) 133 (64.6) 76 (31.3) 22 (51.2)
Side effects
Yes 102 (51.0) 88 (42.7) 163 (67.1) 30 (69.8)
No 98 (49.0) 118 (57.3) 80 (32.9) 13 (30.2)
Side effects (multiple response)
Flushes 75 (37.5) 27 (13.1) 88 (36.2) 18 (41.9)
Myalgia 23 (11.5) 48 (23.3) 103 (42.4) 20 (46.5)
Fatigue/weakness 18 (9.0) 16 (7.8) 28 (11.5) 7 (16.3)
Osteopenia 3 (1.5) 21 (10.2) 29 (11.9) 4 (9.3)
Vaginal dryness 9 (4.5) 7 (3.4) 20 (8.2) 7 (16.3)
Weight gain 14 (7.0) 4 (1.9) 12 (4.9) 3 (7.0)
Osteoporosis 4 (2.0) 12 (5.8) 13 (5.3) 4 (9.3)
Depression 5 (2.5) 10 (4.9) 12 (4.9) 3 (7.0)
Irregular menstruation 16 (8.0) 1 (0.5) 9 (3.7) 3 (7.0)
Blood loss 9 (4.5) 4 (1.9) 9 (3.7) 3 (7.0)
Oedema 5 (2.5) 7 (3.4) 11 (4.5) 2 (4.7)
Headache 7 (3.5) 1 (0.5) 9 (3.7) 4 (9.3)
Weakened hair and nails 2 (1.0) 2 (1.0) 9 (3.7) 1 (2.3)
Nausea/vomiting 6 (3.0) 5 (2.4) 2 (0.8) 1 (2.3)
Diarrhoea 2 (1.0) 1 (0.5) 8 (3.3) 3 (7.0)
Insomnia 4 (2.0) 0 8 (3.3) 1 (2.3)
Hypercholesterolaemia 0 3 (1.5) 6 (2.5) 0
Memory loss 2 (1.0) 2 (1.0) 3 (1.2) 2 (4.7)
Vision changes 2 (1.0) 0 2 (0.8) 1 (2.3)
Deep vein thrombosis 1 (0.5) 1 (0.5) 2 (0.8) 1 (2.3)
Difficulty concentrating 0 0 2 (0.8) 1 (2.3)
Bone fracture 0 1 (0.5) 1 (0.4) 1 (2.3)
Stroke 0 2 (1.0) 0 1 (2.3)
Pulmonary embolism 0 1 (0.5) 1 (0.4) 1 (2.3)
Cardiotoxicity 0 0 1 (0.4) 0
aDifference from the total N¼ 200, corresponding to missing values. bDifference from the total N¼ 206, corresponding to missing values. cDifference from the total N¼ 243,
corresponding to missing values. dDifference from the total N¼ 43, corresponding to missing values.
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showed a very low degree of concordance among the different
measures, (Osterberg and Blaschke, 2005; Ruddy et al, 2009). Self-
reported adherence is known to overestimate the true values, when
compared with other more reliable measures, such as electronic
control of medical administration (Waterhouse et al, 1993;
Escalada and Griffiths, 2006; Shi et al, 2010). Social desirability
bias and recall bias may account for this (Ruddy et al, 2009). A
remarkable result in our study was the low concordance observed
between physician and self-reported adherence, suggesting a lack
of consistent criteria among physicians and patients in evaluating
adherence, even though physicians clearly rated adherence higher
than did any other alternative measure. In all likelihood,
physicians only report a patient as being non-adherent when the
problem is evident and openly acknowledged during the consulta-
tion, conceivably linked to assessment of adverse effects in some
cases. Although a low probability of false positives is thus to be
expected in such reports, physicians might nonetheless detect a
small percentage of patients with adherence problems.
The explanation for this lack of concordance among the
measures used may lie, to a significant degree, in the different
objectives and sources of information for each measure. Whereas
physicians assess adherence by an evaluative perception of
problems clearly and openly manifested by the patient, such as
lack of response, side effects or questions posed by either one;
pharmacy records, on the other hand, assess cumulative 5 years
persistence as measure of adherence on the basis of an
administrative database that collects information of which patients
are not aware, via a process free of intervention by health
professionals; thereby making it the most reliable and objective
indicator. An accepted assumption in the administrative records is
that drug refills are associated with adherence (assuming pill
intake), especially in the case of long lasting treatments such as
oral endocrine therapy for BC (Cramer et al, 2008). Furthermore,
the use of telephone interviews to measure self-reported adherence
probably led to potential social desirability bias, with an ensuing
overestimation of adherence. Even so, findings from this study do
not allow for a reference method to be selected because results
would need to be checked against biological data that are currently
unavailable. However, the prescription refill is probably the most
reliable method in this context of long-term therapy.
The relationship between explanatory variables and adherence
displayed relevant variation, depending on the adherence measure
considered. Based on physician report, increasing age was
associated with a higher level of treatment adherence, after
adjusting for all relevant variables, which is in line with previous
studies in the literature (Partridge et al, 2003; Barron et al, 2007).
An interesting finding is the fact that adjuvant chemotherapy was
associated with a higher probability of adherence. This is
consistent with a previous cohort study, which also used
persistence as an outcome variable in conjunction with a 4.5-year
follow-up period (Hershman et al, 2010a). A possible explanation
for this finding might be the intensity of therapy as perceived by
the patient and the higher interaction with the physician, which
such treatment necessarily implies. The lack of association
Table 2 Description of adherence measures
% adherencea Physician report Telephone questionnaire Pharmacy administrative database
Physician reportb 94.7 — n¼ 506
0.036 (0.041)
n¼ 673
0.199 (0.028)
Physician reportb
Tamoxifen 93.4 — n¼ 136
0.076 (0.085)
n¼ 193
0.267 (0.053)
Inhibitors 94.7 — n¼ 142
0.050 (0.077)
n¼ 201
0.143 (0.053)
Tamoxifen þ inhibitors 95.7 — n¼ 197
 0.018 (0.046)
n¼ 238
0.019 (0.036)
Others 94.0 — n¼ 31
 0.094 (0.167)
n¼ 41
0.204 (0.095)
Telephone questionnaireb 92.0 n¼ 506
0.036 (0.041)
— n¼ 494
0.102 (0.040)
Telephone questionnaire (high)b
Tamoxifen 88.8 n¼ 136
0.076 (0.085)
— n¼ 132
0.108 (0.070)
Inhibitors 92.6 n¼ 142
0.050 (0.077)
— n¼ 140
0.150 (0.081)
Tamoxifen þ inhibitors 93.8 n¼ 197
 0.018 (0.046)
— n¼ 192
0.051 (0.067)
Others 91.0 n¼ 31
 0.094 (0.167)
— n¼ 30
0.019 (0.130)
Pharmacy administrative databaseb 74.7 n¼ 673
0.199 (0.028)
n¼ 494
0.102 (0.040)
—
Pharmacy administrative databaseb
Tamoxifen 68.6 n¼ 193
0.267 (0.053)
n¼ 132
0.108 (0.070)
—
Inhibitors 75.5 n¼ 201
0.143 (0.053)
n¼ 140
0.150 (0.081)
—
Tamoxifen þ inhibitors 78.5 n¼ 238
0.019 (0.036)
n¼ 192
0.051 (0.067)
—
Others 74.0 n¼ 41
0.204 (0.095)
n¼ 30
0.019 (0.130)
—
a% Adherence adjusted for centre, age at diagnosis and stage. bConcordance: kappa (s.e. for kappa statistic).
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between adverse effects and non-adherence is unexpected; several
papers have reported this finding (Grunfeld et al, 2005; Atkins and
Fallowfield, 2006; Hershman et al, 2010a), which we failed to
observe; although it has been found non differential adherence in
clinical trials between treatment and placebo group (Fisher et al,
1996); indicating that the relationship is more complex than
usually assumed. However, it should be stressed again that these
findings are based on physician report, which could bias the
relationship. Finally, when compared with one-drug treatment,
sequential oral endocrine therapy was associated with an increased
probability of adherence. This could be relevant, bearing in mind
the Catalonian guideline recommends the adoption of this
therapeutic approach (Manchon et al, 2010) and a progressive
reduction in the indication of one-drug treatment in endocrine
therapy for early BC.
It is interesting to notice that the results observed are quite
consistent with the physician report when the multivariate analysis
is analysed using refill prescriptions as dependent variable. Older
age, adjuvant chemotherapy, sequential treatment or aromatase
inhibitors alone as endocrine treatment in comparison to
tamoxifen alone were significantly associated with higher prob-
ability of adherence. These results increased the consistency of the
observations regarding the relevant variables associated with
adherence. Here, it is worth mentioning the fact the adjuvant
Table 3 Prevalence and odds ratio (OR) associated with adherence for each of the methods used
Physician report Telephone questionnaire Pharmacy administrative database
n (%) ORa n (%) ORb n (%) ORc
Age at diagnosis
p49 183 (90.7) 1 138 (84.8) 1 176 (64.8) 1
50–74 419 (95.5) 1.71 (0.72–4.06) 330 (94.2) 2.75 (1.41–5.36)a 409 (79.0) 1.67 (1.03–2.70)a
X75 90 (94.4) 2.56 (0.68–9.63) 38 (86.8) 1.07 (0.37–3.12) 88 (67.0) 1.60 (0.76–3.36)
P-value 0.075 0.003a 0.001a
Stage
I 321 (93.5) 1 249 (92.8) 1 314 (74.2) 1
IIA 200 (95.0) 0.89 (0.36–2.19) 142 (90.1) 0.81 (0.38–1.71) 192 (78.1) 1.09 (0.67–1.77)
IIB 93 (93.5) 0.72 (0.25–2.1) 64 (87.5) 0.63 (0.25–1.56) 91 (64.8) 0.57 (0.32–1)a
IIIA 42 (95.2) 1.2 (0.24–5.96) 30 (90.0) 0.62 (0.16–2.33) 40 (77.5) 1.09 (0.46–2.58)
TNMx 36 (94.4) 1.01 (0.2–5.09) 21 (90.5) 0.87 (0.17–4.50) 36 (63.9) 0.67 (0.29–1.58)
P-value 0.953 0.718 0.101
Surgical treatment
Yes 681 (94.1) 1 505 (91.1) 1 663 (74.2) 1
No 11 (90.9) 1.63 (0.16–17.14) 1 (100.0) — 10 (40.0) 2.14 (0.51–8.98)
P-value 0.654 0.911 0.015a
Type of surgical treatment
Conservative breast surgery 536 (93.7) 1 394 (91.4) 1 523 (74.8) 1
Radical breast surgery 145 (95.9) 1.34 (0.51–3.5) 111 (90.1) 1.09 (0.50–2.34) 140 (72.1) 1.47 (0.80–2.68)
P-value 0.426 0.706 0.516
Radiotherapy
No 132 (91.7) 1 85 (91.8) 1 128 (62.5) 1
Yes 560 (94.6) 1.8 (0.8–4.05) 421 (91.0) 0.65 (0.27–1.57) 545 (76.3) 1.48 (0.93–2.36)
P-value 0.193 0.815 0.001a
Neoadjuvant chemotherapy
No 598 (94.1) 1 445 (90.8) 1 582 (74.6) 1
Yes 94 (93.6) 0.79 (0.28–2.2) 61 (93.4) 1.79 (0.59–5.44) 91 (68.1) 0.57 (0.33–1)
P-value 0.840 0.494 0.195
Adjuvant chemotherapy
No 331 (92.1) 1 231 (91.8) 1 322 (68.6) 1
Yes 361 (95.8) 2.14 (1.01–4.53)a 275 (90.5) 0.89 (0.44–1.81) 351 (78.3) 1.60 (1.05–2.43)a
P-value 0.039a 0.628 0.004a
Endocrine therapy
Tamoxifen 200 (89.0) 1 136 (89.7) 1 193 (60.6) 1
Inhibitors 206 (94.7) 2.06 (0.82–5.17) 142 (90.9) 0.53 (0.19–1.48) 201 (78.1) 2 (1.18–3.38)a
Tamoxifen þ inhibitors 243 (98.4) 6.28 (1.93–20.45)a 197 (92.9) 0.65 (0.26–1.64) 238 (84.5) 2.27 (1.34–3.84)a
Others 43 (94.1) 1.24 (0.38–4.03) 31 (87.1) 0.52 (0.15–1.84) 41 (51.2) 0.55 (0.27–1.13)
P-value o0.001a 0.630 o0.001a
Side effectsb
No 309 (92.2) 1 209 (90.9) 1 298 (69.5) 1
Yes 383 (95.6) 1.81 (0.81–4.02) 297 (91.2) 1.06 (0.49–2.28) 375 (77.1) 1.25 (0.81–1.93)
P-value 0.048a 0.508 0.016a
Abbreviations: ORa¼ adjusted for centre, age at diagnosis, adjuvant chemotherapy, adverse effects and endocrine therapy; ORb¼ adjusted for centre, age at diagnosis;
ORc¼ adjusted for centre, age at diagnosis, adjuvant chemotherapy, radiotherapy, side effects and endocrine therapy. n (%)¼ number of cases (% adherence); P-value: w2-test.
aStatistical significance, Po0.05. bAdverse effects of physician report.
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radiotherapy was also associated with adherence, which adds
support to the fact that intense treatment and its correlate of visits
with professionals and health care contacts could be a possible
explanation for this finding. Interestingly, side effects showed no
significant relationship with adherence although a higher percen-
tage of adverse effects was associated with higher adherence in
bivariate relationship. The explanation may possibly lie in the
association described by patients between the drug’s perceived
efficacy and the presence of adverse effects (Bell, 2009). Focusing
on patients’ self-reports, only age was significantly associated with
adherence. The role of age is consistent with other measures used
here and in other studies (Ruddy et al, 2009), as well as the lack of
a clear pattern with other demographic and socio-economic
variables. This lack of association with variables other than age
prevents a profile of patients with a higher risk of non-adherence
from being drawn up.
Some limitations of this study should be considered. It was a
retrospective study with a 5-year follow-up of refill rates, and
subjects’ answers to questionnaire might have been influenced by
recall bias. Furthermore, as physicians’ reports were based on
clinical records, there is the potential problem of possible
omissions of patients’ non-adherence. Although the use of an
administrative database aimed at reimbursing the cost of drugs to
the public health care system raises the point that the database was
never intended for such a purpose, this should nevertheless be
counterbalanced by the fact that patients’ lack of awareness and
the database’s mandatory nature probably serve to make its
content highly reliable in terms of prescription-refill rates.
Moreover, this database allowed for a 5-year follow-up, which
was not the case in several previous studies (Lebovits et al, 1990;
Waterhouse et al, 1993; Murthy et al, 2002; Partridge et al, 2003;
Atkins and Fallowfield, 2006; Barron et al, 2007; Thompson et al,
2007). In fact, relevant aspect of our study was its inclusion of all
treatment regimens for oral endocrine therapy. Finally, because of
sample size, it has not been possible to explore in depth the role of
individual adverse effects on adherence.
In conclusion, non-adherence was found to be a relevant health
problem among BC patients on oral endocrine therapy. About
three quarters of all study subjects fully completed the 5-year
treatment recommended in the clinical guidelines. Although young
age at diagnosis was the variable most clearly associated with non-
adherence to treatment, sequential as opposed to one-drug
therapy, adjuvant chemotherapy and radiotherapy were all
associated with a higher probability of adherence with treatment.
A relevant result of this study, however, was the lack of agreement
among the different measures of adherence, the reason for which
probably goes beyond the fact that they might be measuring
different elements of a similar concept or be drawn from different
data sources. The relevant question remains the need to assume
that the adherence in daily clinical practice depends on how we
measure it.
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